<DOC>
	<DOCNO>NCT01460914</DOCNO>
	<brief_summary>Extracorporeal Photopheresis ( ECP ) form apheresis photodynamic therapy peripheral blood treat 8-methoxypsoralen , activate UV light . ECP currently standard therapy cutaneous T-cell lymphoma ( CTCL ) also effective graft-versus-host disease ( GVHD ) . The investigator would like study outcome ( response rate ) patient receive ECP treatment factor relate disease treatment , well procedural event , complication .</brief_summary>
	<brief_title>Outcomes Cutaneous T-Cell Lymphoma Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment</brief_title>
	<detailed_description>The investigator intend report outcome inception procedure Dartmouth-Hitchcock Medical Center ( DHMC ) May 2008 9/30/11 . Additionally , investigator would like maintain prospective database patient new patient data collect updating outcome .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Patients receive Extracorporeal Photopheresis treatment Treated DartmouthHitchcock Medical Center Must 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ECP</keyword>
	<keyword>CTCL</keyword>
	<keyword>Extracorporeal photopheresis</keyword>
	<keyword>Cutaneous T Cell Lymphoma</keyword>
	<keyword>GVHD</keyword>
	<keyword>Graft versus host disease</keyword>
</DOC>